Amplitude Inc vs Moderna, Inc. — how do they compare? Amplitude Inc trades at $12.5 (market cap $1.59B), while Moderna, Inc. trades at $60.36 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 15.2× Amplitude Inc's market cap, and Amplitude Inc is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| AMPL | MRNA | |
|---|---|---|
Market Cap | $1.59B | $24.18B |
Sector | Technology | Health |
52-Week High | $12.69 | $81.80 |
52-Week Low | $5.61 | $22.36 |
Enterprise Value | $1.45B | $20.33B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Trailing returns across standard periods
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →